What does the research say about mucosal healing?
Mucosal healing is the recognised therapeutic endpoint in ulcerative colitis and a research focus across inflammatory bowel disease, malnutrition enteropathy and oral mucosal injury. Here is what the registered studies a
Mucosal healing is the restoration of an intact epithelial lining at a site of ulceration or inflammatory damage, and in ulcerative colitis (UC) it is described in the clinical literature as the best available therapeutic endpoint [3]. The term is used across several disease contexts rather than one: colonic ulceration in inflammatory bowel disease (IBD), malnutrition enteropathy in children with severe acute malnutrition, and oral mucosal injury in oncologic and surgical settings [4][5][6]. Because repeated colonoscopy is poorly accepted by patients, a substantial part of the research effort has gone into non-invasive proxies — fecal and serum biomarkers intended to predict endoscopic healing without repeat endoscopy [3].
The mechanistic work in this area centres on epithelial regeneration, barrier integrity and the signalling that governs them, including the NAD-dependent deacetylase SIRT1 / STAT3 axis examined in a murine colitis model [1], and on gene expression and mitochondrial function in biopsies taken from healing versus non-healing ulcers [4].
Research Studies
GHK-Cu and the SIRT1/STAT3 pathway in DSS-induced murine colitis
Glycyl-l-histidyl-lysine-copper (GHK-Cu) has known anti-inflammatory properties, but its mechanisms in UC were previously undefined. A study was designed to evaluate GHK-Cu systematically in a dextran sulfate sodium (DSS)-induced murine model of UC, with emphasis on its regulatory effects on the SIRT1/STAT3 signalling pathway. UC was induced in BALB/c mice [1]. This is animal-model work; no human mucosal healing endpoint is reported in the evidence available here.
Fecal and serum biomarkers as predictors of mucosal healing in UC
A registered study addresses the practical obstacle that mucosal healing, while the best therapeutic endpoint, is limited in daily practice by the low acceptability of repeated colonoscopies. Fecal biomarkers are proposed as alternatives. Fecal calprotectin has shown very good negative predictive value for eliminating an IBD diagnosis, good correlation with endoscopic activity, and good ability to predict relapse. Several groups, including the study team, have reported that fecal chitinase 3-like 1 (CHI3L1), matrix metalloprotease type 9 (MMP-9), and the serum markers neutrophil gelatinase B-complex associated lipocalin (NGAL)-MMP9 and serum CHI3L1 may perform better [3].
Non-healing versus iatrogenic ulcers: gene expression and mitochondrial function
A separate registered study compares non-healing colonic ulcers in IBD patients against iatrogenic colonic ulcers (biopsy sites) in healthy controls and in patients with rheumatoid or psoriatic arthritis. Participants are biopsied at baseline and again at follow-up in a "biopsy of the biopsy" design, and the biopsies are used to reveal patterns in gene expression and mitochondrial function during ulcer healing [4]. The comparison is between patient groups, not between interventions.
Lactobacillus probiotics and trace elements added to infliximab in UC
An open-label, parallel, prospective interventional study is evaluating the efficacy and safety of lactobacillus probiotics or trace elements when added to infliximab for maintaining remission in UC, and comparing the two add-on approaches against each other. Recruitment is from the outpatient IBD and gastroenterology clinic of the National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt. Recruited patients are randomly allocated to one of three groups; Group I is to receive 20 billion colony forming units [2].
Four interventions for malnutrition enteropathy in severe acute malnutrition
The TAME study evaluates four approaches against standard care in the treatment of malnutrition enteropathy in children with severe acute malnutrition. In this population, a high pathogen burden damages the intestinal mucosa, which exacerbates nutritional impairment and increases susceptibility to infection and impaired epithelial regeneration. Enteropathy is characterised by multiple epithelial breaches, microbial translocation from the gut lumen to the systemic circulation, and systemic inflammation. The four interventions — colostrum, N-acetyl glucosamine, teduglutide, and budesonide — are given for 14 days [5].
Zinc L-carnosine and the oral mucosa
A systematic review and meta-analysis examined zinc L-carnosine (ZnC), a cytoprotective compound with anti-inflammatory, antioxidant and epithelial reparative properties, for protective and healing effects on the oral mucosa. Oral mucosal injury is a frequent complication in oncologic and surgical settings and affects quality of life [6].
Comparison of study designs across the evidence
| Study | Setting / population | Design | Healing-related measure |
|---|---|---|---|
| GHK-Cu in colitis [1] | BALB/c mice, DSS-induced UC | Preclinical animal model | SIRT1/STAT3 pathway regulation |
| Biomarker prediction [3] | UC patients | Registered study | Fecal calprotectin, CHI3L1, MMP-9; serum NGAL-MMP9, CHI3L1 |
| Ulcer healing biology [4] | IBD patients vs healthy and arthritis controls | Biopsy comparison | Gene expression, mitochondrial function |
| Add-on maintenance [2] | UC patients, NHTMRI Cairo | Open-label, parallel, randomised, three groups | Remission maintenance with infliximab |
| TAME [5] | Children with severe acute malnutrition | Four interventions vs standard care, 14 days | Epithelial regeneration, microbial translocation |
| Zinc L-carnosine [6] | Oral mucosa, oncologic and surgical settings | Systematic review and meta-analysis | Protective and healing effects |
Where the evidence is animal-only or in vitro
The GHK-Cu findings described here come from a murine DSS colitis model and are animal-only [1]. The remaining studies in this evidence set are registered clinical protocols or a systematic review of clinical settings; they do not report a mechanism for GHK-Cu in humans, and no human mucosal healing outcome for GHK-Cu appears in the evidence available here.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only. We do not provide dosing information or medical guidance, and nothing here should be read as a recommendation for any person. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms — https://europepmc.org/article/PMC/PMC12263609
- [2] The Efficacy of Lactobacillous Probiotic and Trace Elements in the Management of Ulcerative Colitis Patients — https://clinicaltrials.gov/study/NCT07758335
- [3] Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis — https://clinicaltrials.gov/study/NCT07653750
- [4] Regulation of Mucosal Healing in Inflammatory Bowel Disease — https://clinicaltrials.gov/study/NCT04504136
- [5] Therapeutic Approaches to Malnutrition Enteropathy — https://clinicaltrials.gov/study/NCT03716115
- [6] Protective and Healing Effects of Zinc L-Carnosine on the Oral Mucosa: A Systematic Review and Meta-Analysis — https://pubmed.ncbi.nlm.nih.gov/42505716/